| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. | Director | Stock Option (right to buy) | 17,126 | 12 Feb 2026 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ELVN | Enliven Therapeutics, Inc. | 12 Feb 2026 | 1 | $0 | 4 | Director | 17 Feb 2026, 19:56 |
| ELVN | Enliven Therapeutics, Inc. | 06 Feb 2025 | 1 | $0 | 4 | Director | 10 Feb 2025, 17:35 |
| ELVN | Enliven Therapeutics, Inc. | 13 Feb 2024 | 1 | $0 | 4/A | Director | 20 Feb 2024, 19:27 |
| ELVN | Enliven Therapeutics, Inc. | 13 Feb 2024 | 1 | $0 | 4 | Director | 15 Feb 2024, 20:48 |
| ELVN | Enliven Therapeutics, Inc. | 23 Feb 2023 | 1 | $0 | 4 | Director | 06 Apr 2023, 20:17 |
| ELVN | Enliven Therapeutics, Inc. | 23 Feb 2023 | 0 | $0 | 3 | Director | 27 Feb 2023, 20:47 |
| ELVN | Enliven Therapeutics, Inc. | 23 Feb 2023 | 1 | $0 | 4 | Director | 27 Feb 2023, 20:43 |